Ekopak just announced a long term strategic partnership with an unnamed European infrastructure partner for the development of (large) WaaS projects. Many details are still unknown and management was not (yet) available for comments. The partnership introduces a minimum of €150m in off balance sheet funding over the next three years that will be deployed through dedicated asset companies financed with senior non recourse debt and majority equity from the infrastructure partner. As part of the pa...
We upgrade our recommendation to Accumulate and raise our price target to €135.0 from €110.0 on multiple expansion over the next 6 to 12 months. We leave our EPS estimates for FY26-27 unchanged, but increase our price target to 22x FY27 EPS. Our previous target was based on 20x FY26 EPS, but we roll forward on a 10% higher multiple as the sentiment towards grid operators benefits from the “wall of money” into datacenters, while grid connection is the bottleneck. It can take years before the ROE ...
MaaT announced that the first patient has been randomised in the investigator sponsored multicenter phase 2 (IMMUNOLIFE) trial evaluating MaaT033 (microbiome therapy, oral capsule) in combination with cemiplimab (anti PD-1 antibody) in patients with advanced non-small cell lung cancer (NSCLC) who have developed resistance to PD-1/PD-L1 blockade following antibiotic (ATB) exposure and who present ATB-induced gut dysbiosis. Primary results after 1-year follow-up post-treatment could be expected in...
We hosted our 29th ODDO BHF Forum in Lyon on 8 and 9 January 2026. In total, 220 companies presented over the two days. In the following note, we provide some initial feedback from the companies on Day 2, in addition to Day 1 feedback (Link to Day 1 feedback). Key positive companies were Corbion, DEME, Elia Group, Knorr Bremse, Sulzer, Séché Environnement, Fraport, Vallourec and TUI. More cautious companies were Arkema, Fastned, INWIT, Manitou, Roche Bobois, Téléperformance, and Colonial SFL. T...
Melexis: update on the share buy-back program Press release - Regulated Information Ieper, Belgium – 5 January 2026, 17.45 hrs CET Melexis reports the purchase of 6,600 Melexis shares on Euronext Brussels in the period from 29 December 2025 to 2 January 2026, related to the share buy-back program announced on 10 December 2025. Trade dateTotal shares purchasedAverage price (€)Min price (€)Max price (€)Buyback amount (€)29/12/20253,60056.8256.4557.00204,56830/12/20253,00057.2857.0057.60171,82931/12/2025-----1/1/2026-----2/1/2026-----TOTAL6,60057.0356.4557.60376,397 Under the current share...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.